Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $55.33 Average PT from Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $52.40.

Several equities analysts have recently commented on the stock. Needham & Company LLC raised shares of Establishment Labs from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research report on Wednesday, May 14th. Wall Street Zen cut shares of Establishment Labs from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Stephens reiterated an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Finally, BTIG Research assumed coverage on Establishment Labs in a research note on Friday, May 16th. They issued a “buy” rating and a $62.00 price objective on the stock.

Institutional Investors Weigh In On Establishment Labs

A number of large investors have recently made changes to their positions in ESTA. Toronto Dominion Bank acquired a new stake in Establishment Labs during the 4th quarter worth about $24,879,000. Brown Advisory Inc. increased its position in Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock worth $107,729,000 after buying an additional 438,057 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Establishment Labs by 29.3% in the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock valued at $88,064,000 after acquiring an additional 433,484 shares in the last quarter. Voya Investment Management LLC raised its position in shares of Establishment Labs by 7,249.5% in the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company’s stock valued at $18,809,000 after purchasing an additional 402,707 shares during the period. Finally, Millennium Management LLC lifted its position in Establishment Labs by 96.9% during the 4th quarter. Millennium Management LLC now owns 711,691 shares of the company’s stock worth $32,788,000 after acquiring an additional 350,213 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $38.49 on Tuesday. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $52.41. The business has a 50-day moving average of $33.44 and a 200-day moving average of $37.45. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -14.92 and a beta of 0.74.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business had revenue of $41.38 million for the quarter, compared to analyst estimates of $41.15 million. During the same period in the previous year, the company earned ($0.58) earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, equities analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.